A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Efatutazone (Primary)
- Indications Liposarcoma
- Focus Therapeutic Use
- 16 Nov 2016 Planned number of patients changed from 36 to 30.
- 28 Oct 2016 Status changed from suspended to recruiting.
- 25 Jul 2016 Status changed from active, no longer recruiting to suspended.